With the possibility of a no-deal Brexit scenario becoming more likely, the Medicines and healthcare products Regulatory Agency (MHRA) in the UK has edited its guidelines for clinical trials, medical devices, and medicines, to include updates on what will change should a no-deal exit option be selected on March 29, the date set for Brexit. Find out what MHRA is recommending, how issues like potential medicines shortages will be mitigated, how registration for medical devices and IVDs will change after March 29, what a no-deal exit means for UK-based notified bodies, and more.